ARTICLE | Clinical News

FDA accepts NDA for Indivior's sustained-release risperidone

December 15, 2017 7:46 PM UTC

Indivior plc (LSE:INDV) said FDA accepted for review an NDA for RBP-7000 to treat schizophrenia. The PDUFA date is July 28.

In September, Indivior gained rights to IP for RBP-7000 from Durect Corp. (NASDAQ:DRRX) for $12.5 million up front. Durect is eligible for an additional $5 million upon NDA approval. The patent rights extend through at least 2026...

BCIQ Company Profiles

Durect Corp.

Indivior plc